<SEC-DOCUMENT>0001062993-18-001169.txt : 20180312
<SEC-HEADER>0001062993-18-001169.hdr.sgml : 20180312
<ACCEPTANCE-DATETIME>20180312125513
ACCESSION NUMBER:		0001062993-18-001169
CONFORMED SUBMISSION TYPE:	CB/A
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20180312

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CanniMed Therapeutics Inc.
		CENTRAL INDEX KEY:			0001695631
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		CB/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-90192
		FILM NUMBER:		18682794

	BUSINESS ADDRESS:	
		STREET 1:		1 PLANT TECHNOLOGY ROAD
		STREET 2:		BOX 19A, RR#5
		CITY:			SASKATOON
		STATE:			A9
		ZIP:			S7K 3J8
		BUSINESS PHONE:		306-975-1207

	MAIL ADDRESS:	
		STREET 1:		1 PLANT TECHNOLOGY ROAD
		STREET 2:		BOX 19A, RR#5
		CITY:			SASKATOON
		STATE:			A9
		ZIP:			S7K 3J8

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AURORA CANNABIS INC
		CENTRAL INDEX KEY:			0001683541
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		CB/A

	BUSINESS ADDRESS:	
		STREET 1:		1500 - 1199 WEST HASTINGS ST.
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 3T5
		BUSINESS PHONE:		604-362-5207

	MAIL ADDRESS:	
		STREET 1:		1500 - 1199 WEST HASTINGS ST.
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 3T5
</SEC-HEADER>
<DOCUMENT>
<TYPE>CB/A
<SEQUENCE>1
<FILENAME>formcba.htm
<DESCRIPTION>CB/A
<TEXT>
<HTML>
<HEAD>
   <TITLE>Aurora Cannabis Inc.: Form CB/A - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES </FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT></B><BR><B>Washington, D.C.
20549 </B></P>
<P align=center><B><FONT size=5>Form CB/A </FONT></B></P>
<P align=center><B>TENDER OFFER/RIGHTS OFFERING NOTIFICATION FORM </B></P>
<P align=center><B>(AMENDMENT NO. 7) </B></P>
<P align=justify>Please place an X in the box(es) to designate the appropriate
rule provision(s) relied upon to file this Form: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="65%" >Securities Act Rule 801 (Rights
      Offering) </TD>
    <TD align=left width="30%">[ &nbsp;] </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="65%" >Securities Act Rule 802 (Exchange
      Offer) </TD>
    <TD align=left width="30%">[X] </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="65%" >Exchange Act Rule 13e-4(h)(8)
      (Issuer Tender Offer) </TD>
    <TD align=left width="30%">[ &nbsp;] </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="65%" >Exchange Act Rule 14d-1(c) (Third
      Party Tender Offer) </TD>
    <TD align=left width="30%">[&nbsp; ] </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="65%" >Exchange Act Rule 14e-2(d)
      (Subject Company Response) </TD>
    <TD align=left width="30%">[ &nbsp;] </TD></TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD width="65%" >&nbsp;</TD>
    <TD width="30%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left colSpan=2 >Filed or submitted in paper if
      permitted by Regulation S-T Rule 101(b)(8) </TD>
    <TD align=left width="30%">[&nbsp; ] </TD></TR></TABLE>
<P align=justify>Note: Regulation S-T Rule 101(b)(8) only permits the filing or
submission of a Form CB in paper by a party that is not subject to the reporting
requirements of Section 13 or 15(d) of the Exchange Act. </P>
<P align=center><B><U><FONT size=5>CanniMed Therapeutics Inc.
</FONT></U></B><BR>(Name of Subject Company) </P>
<P align=center><B><U>N/A </U></B><BR>(Translation of Subject Company&#146;s Name
into English (if applicable)) </P>
<P align=center><B><U>Canada </U></B><BR>(Jurisdiction of Subject Company&#146;s
Incorporation or Organization) </P>
<P align=center><B><U>Aurora Cannabis Inc. </U></B><BR>(Name of Person(s)
Furnishing Form) </P>
<P align=center><B><U>Common Stock </U></B><BR>(Title of Class of Subject
Securities) </P>
<P align=center><B><U>13767U </U></B><BR>(CUSIP Number of Class of Securities
(if applicable)) </P>
<P align=center><B>CanniMed Therapeutics Inc. </B><BR><B>1 Plant Technology Rd.
Box 19A, RR#5 </B><BR><B>Saskatoon, SK,</B><BR><B>Canada, S7K 3J8
</B><BR><B><U>Telephone: (306) 978-6848 </U></B><BR>(Name, Address (including
zip code) and Telephone Number (including area code) of <BR>Person(s) Authorized
to Receive Notices and Communications on Behalf of Subject Company) </P>
<P align=center><B><U>November 24, 2017 </U></B><BR>(Date Tender Offer/Rights
Offering Commenced) </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=center>- 2 - </P>
<P align=center><B>PART I - INFORMATION SENT TO SECURITY HOLDERS </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>Item 1.</B> </TD>
    <TD align=left width="90%"><B>Home Jurisdiction Documents</B>
  </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%" ><B>(a)</B> </TD>
    <TD>
      <P align=justify><B>The following documents have been delivered to holders
      of securities of, or published in the home jurisdiction of CanniMed
      Therapeutics Inc. and were required to be disseminated to U.S. security
      holders or published in the United States:</B></P></TD></TR></TABLE>
<P style="MARGIN-LEFT: 5%" align=justify>On November 24, 2017, Aurora Cannabis
Inc. commenced an offer to purchase all of the common shares of CanniMed
Therapeutics Inc. On November 24, 2017, Aurora Cannabis Inc. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="5%">&#149; </TD>
    <TD align=left width="90%">
      <P align=justify>filed with Canadian securities authorities in British
      Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova
      Scotia, Prince Edward Island, Newfoundland and Quebec, via the System for
      Electronic Document Analysis and Retrieval, </P></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="5%">&nbsp; </TD>
    <TD width="90%">
      <P align=justify></P></TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="5%">&#149; </TD>
    <TD align=left width="90%">
      <P align=justify>caused to be delivered to holders of securities of
      CanniMed Therapeutics Inc., and </P></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="5%">&nbsp; </TD>
    <TD width="90%">
      <P align=justify></P></TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="5%">&#149; </TD>
    <TD align=left width="90%">
      <P align=justify>furnished to the Securities and Exchange Commission on
      Form CB, </P></TD></TR></TABLE>
<P style="MARGIN-LEFT: 5%" align=justify>its Offer to Purchase and Circular,
together with the exhibits referenced therein.<SUP>1 </SUP></P>
<P style="MARGIN-LEFT: 5%" align=justify>On January 12, 2018, Aurora Cannabis
Inc.</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="5%">&#149; </TD>
    <TD align=left width="90%">
      <P align=justify>filed with Canadian securities authorities in British
      Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova
      Scotia, Prince Edward Island, Newfoundland and Quebec, via the System for
      Electronic Document Analysis and Retrieval, </P></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="5%">&nbsp; </TD>
    <TD width="90%">
      <P align=justify></P></TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="5%">&#149; </TD>
    <TD align=left width="90%">
      <P align=justify>caused to be delivered to holders of securities of
      CanniMed Therapeutics Inc., and </P></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="5%">&nbsp; </TD>
    <TD width="90%">
      <P align=justify></P></TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="5%">&#149; </TD>
    <TD align=left width="90%">
      <P align=justify>furnished to the Securities and Exchange Commission as
      Exhibit 1.1 to Amendment No. 1 to Aurora Cannabis Inc.&#146;s Form CB,
  </P></TD></TR></TABLE>
<P style="MARGIN-LEFT: 5%" align=justify>its Notice of Change of Information
Relating to the Aurora Cannabis Inc. Offer to Purchase All of the Common Shares
of CanniMed Therapeutics Inc.<SUP>2 </SUP></P>
<P style="MARGIN-LEFT: 5%" align=justify>On January 12, 2018, Aurora Cannabis
Inc. issued the following news releases pursuant to the orders of the Financial
and Consumer Affairs Authority of Saskatchewan and the Ontario Securities
Commission dated December 22, 2017: </P>
<P style="MARGIN-LEFT: 10%" align=justify>News release of Aurora Cannabis Inc.
dated November 14, 2017, amended and restated with additional information on
January 12, 2018, regarding submission of proposal to CanniMed Therapeutics Inc.
board and execution of lock-up agreements with CanniMed shareholders<SUP>2
</SUP></P>
<P style="MARGIN-LEFT: 10%" align=justify>News release of Aurora Cannabis Inc.
dated November 20, 2017, amended and restated with additional information on
January 12, 2018, regarding announcement of intention to launch takeover bid for
CanniMed Therapeutics Inc.<SUP>2 </SUP></P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_3></A>
<P align=center>- 3 - </P>
<P style="MARGIN-LEFT: 5%" align=justify>On December 27, 2017, Aurora Cannabis
Inc. issued the following news release to report the results of hearings held
before the Financial and Consumer Affairs Authority of Saskatchewan and the
Ontario Securities Commission on December 20-21, 2017, in connection with Aurora
Cannabis Inc.&#146;s offer to purchase all of the common shares of CanniMed
Therapeutics Inc.: </P>
<P style="MARGIN-LEFT: 10%" align=justify>News release of Aurora Cannabis Inc.
dated December 27, 2017<SUP>2 </SUP></P>
<P style="MARGIN-LEFT: 5%" align=justify>As permitted under Canadian takeover
bid rules, Aurora Cannabis Inc. has completed certain normal course purchases of
CanniMed Therapeutics Inc. common shares through the facilities of The Toronto
Stock Exchange, as disclosed in the following news releases: </P>
<P style="MARGIN-LEFT: 10%" align=justify>News release of Aurora Cannabis Inc.
dated December 29, 2017, announcing the purchase of 450,000 shares of CanniMed
Therapeutics Inc.<SUP>2 </SUP></P>
<P style="MARGIN-LEFT: 10%" align=justify>News release of Aurora Cannabis Inc.
dated January 2, 2018, announcing the purchase of 116,000 shares of CanniMed
Therapeutics Inc.<SUP>2 </SUP></P>
<P style="MARGIN-LEFT: 10%" align=justify>News release of Aurora Cannabis Inc.
dated January 4, 2018, announcing the purchase of 91,800 shares of CanniMed
Therapeutics Inc.<SUP>2 </SUP></P>
<P style="MARGIN-LEFT: 10%" align=justify>News release of Aurora Cannabis Inc.
dated January 5, 2018, announcing the purchase of 24,600 shares of CanniMed
Therapeutics Inc.<SUP>2 </SUP></P>
<P style="MARGIN-LEFT: 10%" align=justify>News release of Aurora Cannabis Inc.
dated January 12, 2018, announcing the purchase of 7,400 shares of CanniMed
Therapeutics Inc.<SUP>2 </SUP></P>
<P style="MARGIN-LEFT: 10%" align=justify>News release of Aurora Cannabis Inc.
dated January 15, 2018, announcing the purchase of 10,800 shares of CanniMed
Therapeutics Inc.<SUP> 3</SUP> </P>
<P style="MARGIN-LEFT: 5%" align=justify>On January 24, 2018, Aurora Cannabis
Inc. issued the following joint news release with CanniMed Therapeutics Inc. to
announce the entry into a support agreement and new offer terms, in connection
with Aurora Cannabis Inc.&#146;s offer to purchase all of the common shares of
CanniMed Therapeutics Inc.: </P>
<P style="MARGIN-LEFT: 10%" align=justify>News release of Aurora Cannabis Inc.
and CanniMed Therapeutics Inc. dated January 24, 2018, announcing the entry into
a support agreement and new offer terms by Aurora Cannabis.<SUP>4 </SUP></P>
<P style="MARGIN-LEFT: 5%" align=justify>On January 26, 2018, Aurora Cannabis
Inc. filed with Canadian Securities Administrators in British Columbia, Alberta,
Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, Prince Edward
Island, Newfoundland and Quebec, via the System for Electronic Document Analysis
and Retrieval, the following document: </P>
<P style="MARGIN-LEFT: 10%" align=justify>Support Agreement between Aurora
Cannabis Inc. and CanniMed Therapeutics Inc. dated January 24, 2018.<SUP>5
</SUP></P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_4></A>
<P align=center>- 4 - </P>
<P style="MARGIN-LEFT: 5%" align=justify>On January 26, 2018, Aurora Cannabis
Inc. filed with Canadian Securities Administrators in British Columbia, Alberta,
Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, Prince Edward
Island, Newfoundland and Quebec, via the System for Electronic Document Analysis
and Retrieval, the following material change report related to its entry into
the Support Agreement with CanniMed Therapeutics Inc. in connection with Aurora
Cannabis Inc.&#146;s offer to purchase all issued and outstanding common shares of
CanniMed Therapeutics Inc.: </P>
<P style="MARGIN-LEFT: 10%" align=justify>Material Change Report of Aurora
Cannabis Inc., dated January 26, 2018, related to its entry into the Support
Agreement with CanniMed Therapeutics Inc. in connection with Aurora Cannabis
Inc.&#146;s offer to purchase all issued and outstanding common shares of CanniMed
Therapeutics Inc.<SUP>5 </SUP></P>
<P style="MARGIN-LEFT: 5%" align=justify>On February 6, 2018, Aurora Cannabis
Inc. Aurora Cannabis Inc. filed with Canadian securities authorities in British
Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia,
Prince Edward Island, Newfoundland and Quebec via the System for Electronic
Document Analysis and Retrieval, and caused to be delivered to holders of common
shares of CanniMed Therapeutics Inc., the following documents: </P>
<P style="MARGIN-LEFT: 10%" align=justify>its Notice of Variation to the Aurora
Cannabis Inc. Offer to Purchase All of the Common Shares of CanniMed
Therapeutics Inc.<SUP>6 </SUP></P>
<P style="MARGIN-LEFT: 10%" align=justify>Amended Letter of
Transmittal<SUP>6</SUP></P>
<P style="MARGIN-LEFT: 5%" align=justify>On February 6, 2018, Aurora Cannabis
Inc. Aurora Cannabis Inc. filed with Canadian securities authorities in British
Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia,
Prince Edward Island, Newfoundland and Quebec via the System for Electronic
Document Analysis and Retrieval, the following documents: </P>
<P style="MARGIN-LEFT: 10%" align=justify>Lock-up Agreement between Aurora
Cannabis Inc. and Brent Zettl dated January 29, 2018<SUP>7 </SUP></P>
<P style="MARGIN-LEFT: 10%" align=justify>Lock-up Agreement between Aurora
Cannabis Inc. and [Redacted] dated February 3, 2018<SUP>7</SUP> </P>
<P style="MARGIN-LEFT: 10%" align=justify>Lock-up Agreement between Aurora
Cannabis Inc. and [Redacted] dated January 29, 2018<SUP>7</SUP> </P>
<P style="MARGIN-LEFT: 10%" align=justify>Lock-up Agreement between Aurora
Cannabis Inc. and [Redacted] dated January 29, 2018<SUP>7</SUP> </P>
<P style="MARGIN-LEFT: 10%" align=justify>Lock-up Agreement between Aurora
Cannabis Inc. and [Redacted] dated January 31, 2018<SUP>7</SUP> </P>
<P style="MARGIN-LEFT: 10%" align=justify>Lock-up Agreement between Aurora
Cannabis Inc. and [Redacted] dated February 2, 2018<SUP>7</SUP> </P>
<P style="MARGIN-LEFT: 10%" align=justify>Lock-up Agreement between Aurora
Cannabis Inc. and [Redacted] dated January 31, 2018<SUP>7</SUP> </P>
<P style="MARGIN-LEFT: 10%" align=justify>Lock-up Agreement between Aurora
Cannabis Inc. and [Redacted] dated January 29, 2018<sup>7</sup></P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_5></A>
<P align=center>- 5 -</P>
<P style="MARGIN-LEFT: 10%" align=justify>Lock-up Agreement between Aurora
Cannabis Inc. and [Redacted] dated January 31, 2018<SUP>7</SUP> </P>
<P style="MARGIN-LEFT: 10%" align=justify>Lock-up Agreement between Aurora
Cannabis Inc. and [Redacted] dated January 26, 2018<SUP>7</SUP> </P>
<P style="MARGIN-LEFT: 10%" align=justify>Lock-up Agreement between Aurora
Cannabis Inc. and [Redacted] dated January 31, 2018<SUP>7</SUP> </P>
<P style="MARGIN-LEFT: 5%" align=justify><U>Notes</U>: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><sup>1. </sup> </TD>
    <TD>
      <P align=justify>Previously furnished to the Securities and Exchange
      Commission by Aurora Cannabis Inc. on November 27, 2017, as exhibits to
      its Form CB</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD vAlign=top width="5%"><sup>2. </sup> </TD>
    <TD>
      <P align=justify>Previously furnished to the Securities and Exchange
      Commission by Aurora Cannabis Inc. on January 16, 2018 as exhibits to
      Amendment No. 1 to its Form CB</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD vAlign=top width="5%"><sup>3. </sup> </TD>
    <TD>
      <P align=justify>Previously furnished to the Securities and Exchange
      Commission by Aurora Cannabis Inc. on January 17, 2018 as an exhibit to
      Amendment No. 2 to its Form CB</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD vAlign=top width="5%"><sup>4. </sup> </TD>
    <TD>
      <P align=justify>Previously furnished to the Securities and Exchange
      Commission by Aurora Cannabis Inc. on January 26, 2018 as an exhibit to
      Amendment No. 3 to its Form CB</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD vAlign=top width="5%"><sup>5. </sup> </TD>
    <TD>
      <P align=justify>Previously furnished to the Securities and Exchange
      Commission by Aurora Cannabis Inc. on January 30, 2018 as an exhibit to
      Amendment No. 4 to its Form CB</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD vAlign=top width="5%"><sup>6. </sup> </TD>
    <TD>
      <P align=justify>Previously furnished to the Securities and Exchange
      Commission by Aurora Cannabis Inc. on February 8, 2018 as an exhibit to
      Amendment No. 5 to its Form CB</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD vAlign=top width="5%"><sup>7. </sup> </TD>
    <TD>
      <P align=justify>Previously furnished to the Securities and Exchange
      Commission by Aurora Cannabis Inc. on February 9, 2018 as an exhibit to
      Amendment No. 6 to its Form CB</P></TD></TR></TABLE>
<P style="MARGIN-LEFT: 5%" align=justify>On March 9, 2018, Aurora Cannabis Inc.
filed with Canadian securities authorities in British Columbia, Alberta,
Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, Prince Edward
Island, Newfoundland and Quebec via the System for Electronic Document Analysis
and Retrieval, and caused to be delivered to the registered holders of common
shares of CanniMed Therapeutics Inc., the following document: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="10%" ><a href="exhibit1-1.htm">Exhibit 1.1 </a> </TD>
    <TD align=left width="85%">
      <P align=justify><a href="exhibit1-1.htm">its Notice of Variation and Extension to the Aurora
      Cannabis Inc. Offer to Purchase All of the Common Shares of CanniMed
      Therapeutics Inc. dated March 9, 2018 </a> </P></TD></TR></TABLE>
<P style="MARGIN-LEFT: 5%" align=justify>and issued the following news release,
via the System for Electronic Document Analysis and Retrieval, to announce the
success of its Offer to Purchase All of the Common Shares of CanniMed
Therapeutics Inc., its intention to take up tendered Common Shares of CanniMed
Therapeutics Inc. and the mandatory extension of its Offer: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="10%" ><a href="exhibit1-2.htm">Exhibit 1.2 </a> </TD>
    <TD align=left width="85%">
      <P align=justify><a href="exhibit1-2.htm">News Release of Aurora Cannabis Inc. dated March 9, 2018,
      announcing success in its Offer to Purchase All of the Common Shares of
      CanniMed Therapeutics Inc., its intention to take up tendered Common
      Shares of CanniMed Therapeutics Inc. and the mandatory extension of its
      Offer </a></P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_6></A>
<P align=center>- 6 - </P>
<P align=justify><B>(b)</B></P>
<P align=justify>Not applicable. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>Item 2.</B> </TD>
    <TD align=left width="90%">
      <P align=justify><B>Informational Legends</B> </P></TD></TR></TABLE>
<P align=justify>The required legends are included under the heading &#147;NOTICE TO
CANNIMED SHAREHOLDERS IN THE UNITED STATES&#148;, commencing on the page 6 of the
Notice of Variation and Extension to the Aurora Cannabis Inc. Offer to Purchase
All of the Common Shares of CanniMed Therapeutics Inc. </P>
<P align=justify>The required legends were also included:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>under the heading &#147;NOTICE TO CANNIMED SHAREHOLDERS IN THE
      UNITED STATES&#148;, commencing on the page 50 of the Notice of Variation to
      the Aurora Cannabis Inc. Offer to Purchase All of the Common Shares of
      CanniMed Therapeutics Inc., which was furnished to the Securities and
      Exchange Commission as Exhibit 1.1 to Amendment No. 5 to Aurora Cannabis
      Inc.&#146;s Form CB;</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>
      <P align=justify>&nbsp;</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>under the heading &#147;NOTICE TO CANNIMED SHAREHOLDERS IN THE
      UNITED STATES&#148;, commencing on the page 7 of the Notice of Change of
      Information Relating to the Aurora Cannabis Inc. Offer to Purchase All of
      the Common Shares of CanniMed Therapeutics Inc., which was furnished to
      the Securities and Exchange Commission as Exhibit 1.1 to Amendment No. 1
      to Aurora Cannabis Inc.&#146;s Form CB; and</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>
      <P align=justify>&nbsp;</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>under the heading &#147;NOTICE TO HOLDERS IN THE UNITED
      STATES&#148;, commencing on page v of the original Offer to Purchase and
      Circular, which was furnished to the Securities and Exchange Commission as
      Exhibit 1.1 to Aurora Cannabis Inc.&#146;s Form CB.</P></TD></TR></TABLE>
<P align=center><B>PART II - INFORMATION NOT REQUIRED TO BE SENT TO SECURITY
HOLDERS </B></P>
<P align=justify><B>(1) </B></P>
<P align=justify>None. </P>
<P align=center><B>PART III - CONSENT TO SERVICE OF PROCESS </B></P>
<P align=justify>Aurora Cannabis Inc. filed a Form F-X with the United States
Securities and Exchange Commission, appointing an agent for service of process
in connection with the transaction to which this Form CB/A relates when it
furnished the original Offer to Purchase and Circular to the Securities and
Exchange Commission on Form CB on November 24, 2017. </P>
<P align=center><B>PART IV - SIGNATURES </B></P>
<P align=justify>After due inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="50%" colSpan=2><B>AURORA CANNABIS INC.</B> </TD></TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD width="5%">&nbsp; </TD>
    <TD width="45%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="5%">By: </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="45%">/s/
    Glen Ibbott </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="5%">Name: </TD>
    <TD align=left width="45%">Glen Ibbott </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="5%">Title: </TD>
    <TD align=left width="45%">Chief Financial Officer </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="5%">Date: </TD>
    <TD align=left width="45%">March 12, 2018 </TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_7></A>
<P align=center>- 7 - </P>
<P align=center><B>EXHIBIT INDEX </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=left ><B><U>Exhibit</U></B> </TD>
    <TD noWrap align=left width="90%"><B><U>Description</U></B> </TD></TR>
  <TR>
    <TD noWrap >&nbsp; </TD>
    <TD noWrap width="90%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee ><a href="exhibit1-1.htm">1.1</a></TD>
    <TD align=left width="90%" bgColor=#eeeeee><a href="exhibit1-1.htm">Notice of Variation and
      Extension to the Aurora Cannabis Inc. Offer to Purchase All of the Common
      Shares of CanniMed Therapeutics Inc. dated March 9, 2018 </a></TD></TR>
  <TR>
    <TD >&nbsp; </TD>
    <TD width="90%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee ><a href="exhibit1-2.htm">1.2</a></TD>
    <TD align=left width="90%" bgColor=#eeeeee><a href="exhibit1-2.htm">News Release of Aurora Cannabis
      Inc. dated March 9, 2018, announcing success in its Offer to Purchase All
      of the Common Shares of CanniMed Therapeutics Inc., its intention to take
      up tendered Common Shares of CanniMed Therapeutics Inc. and the mandatory
      extension of its Offer </a></TD></TR></TABLE><BR>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>exhibit1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Aurora Cannabis Inc.: Exhibit 1.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<!--$$/page=--><A name=page_1></A>
<P align=justify><B><I>This document is important and requires your immediate
attention. It should be read in conjunction with the Original Offer and Circular
(as defined herein) and the Original Notice of Variation (as defined herein). If
you are in doubt as to how to deal with it, you should consult your investment
dealer, broker, lawyer or other professional advisor. </I></B></P>
<P align=justify><I>Neither this Notice of Variation and Extension, the Original
Offer and Circular (as defined herein) nor the Original Notice of Variation (as
defined herein) has been approved by any securities regulatory authority nor has
any securities regulatory authority passed upon the fairness or merits of the
Offer or upon the adequacy of the information contained in this document. Any
representation to the contrary is an offence. Shareholders in the United States
should read the </I><I>&#147;</I><I>Notice to CanniMed Shareholders in the United
States</I><I>&#148;</I><I> in the Original Notice of Variation. </I></P>
<P align=justify><I>This document does not constitute an offer or a solicitation
to any person in any jurisdiction in which such offer or solicitation is
unlawful. The Offer is not being made to, nor will deposits be accepted from or
on behalf of, CanniMed Shareholders in any jurisdiction in which the making or
acceptance of the Offer would not be in compliance with the laws of such
jurisdiction. However, the Offeror may, in its sole discretion, take such action
as it may deem necessary to extend the Offer to CanniMed Shareholders in any
such jurisdiction.</I></P>
<P align=right>March 9, 2018 </P>
<P align=center><IMG src="exhibit1-1x1x1.jpg" border=0> </P>
<P align=center><B>NOTICE OF VARIATION AND EXTENSION </B></P>
<P align=center><B>RELATING TO THE </B></P>
<P align=center><B>AURORA CANNABIS INC. </B></P>
<P align=center><B>OFFER TO PURCHASE ALL OF THE COMMON SHARES OF </B></P>
<P align=center><B>CANNIMED THERAPEUTICS INC. </B></P>
<P align=center><B>on the basis of, at the election of each holder of a common
share of CanniMed Therapeutics Inc.: </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="15%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>(a)</B> </TD>
    <TD>
      <P align=justify><B>3.40 common shares of Aurora Cannabis Inc. (the
      </B><B>&#147;</B><B>Share Alternative</B><B>&#148;</B><B>);</B></P></TD></TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>(b)</B> </TD>
    <TD>
      <P align=justify><B>$43.00 in cash (</B><B>&#147;</B><B>Cash
      Alternative</B><B>&#148;</B><B>); or</B></P></TD></TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>(c)</B> </TD>
    <TD>
      <P align=justify><B>any combination thereof (the </B><B>&#147;</B><B>Share and
      Cash Alternative</B><B>&#148;</B><B>)</B></P></TD></TR></TABLE>
<P align=center><B>for each common share of CanniMed Therapeutics Inc., as
provided in the Original Notice of Variation. </B></P>
<P align=center><B>The Cash Alternative and Share and Cash Alternative are
subject to proration of maximum aggregate cash </B><BR><B>consideration of
$140,000,000. </B></P>
<P align=justify>Aurora Cannabis Inc. (&#147;<B>Aurora</B>&#148; or the &#147;<B>Offeror</B>&#148;)
has prepared this notice of variation and extension (the &#147;<B>Notice of Variation
and Extension</B>&#148;) to give notice that it is extending its offer to purchase
all of the outstanding common shares (the &#147;<B>CanniMed Shares</B>&#148;) of CanniMed
Therapeutics Inc. (&#147;<B>CanniMed</B>&#148;), described in its offer to purchase dated
November 24, 2017 (the &#147;<B>Original Offer</B>&#148;) and in the takeover bid circular
of Aurora that accompanied the Original Offer, as amended by the notice of
change (the &#147;<B>Notice of Change</B>&#148;) dated January 12, 2018 (the
&#147;<B>Circular</B>&#148;, and, together with the Original Offer, the &#147;<B>Original Offer
and Circular</B>&#148;), as amended by the Offeror&#146;s notice of variation dated
February 5, 2018 (the &#147;<B>Original Notice of Variation</B>&#148;). On March 9, 2018,
with all of the conditions to the Offer having been met, Aurora determined to
take up the 17,847,341 CanniMed Shares deposited to date, which, together with
the 700,600 CanniMed Shares already owned the Offeror, represented 70.66% of the outstanding CanniMed Shares. In accordance with
National Instrument 62-104 <i>Take-Over Bids and Issuer Bids</i>, the Offer is
being amended to extend the expiry time of the Offer to 11:59 p.m. (Pacific
time) on March 24, 2018 (the &#147;<b>Expiry Time</b>&#148;). </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A><BR>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=center>THE OFFER HAS BEEN EXTENDED AND IS NOW OPEN FOR
      ACCEPTANCE UNTIL 11:59 P.M. (PACIFIC TIME) ON MARCH 24, 2018.
</TD></TR></TABLE></DIV>
<P align=justify>Aurora is required (under applicable Canadian Securities Laws)
to extend the period during which CanniMed Shares may be tendered to the Offer
for a period of not less than ten (10) days (the &#147;<B>Mandatory Extension
Period</B>&#148;) after the date of this Notice of Variation and Extension as: each
of the conditions to the Offer have been satisfied or waived by Aurora; the
initial deposit period under the Offer expired as of 11:59 p.m. (Pacific time)
on March 9, 2018; and more than 50% of the outstanding CanniMed Shares,
excluding those beneficially owned (or over which control or direction is
exercised) by Aurora or by any person acting jointly or in concert with Aurora,
have been deposited under the Offer and not withdrawn. </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left>
      <P align=justify>ALL OF THE CONDITIONS OF THE OFFER HAVE BEEN SATISFIED OR
      WAIVED AND 17.847,341 CANNIMED SHARES (OR APPROXIMATELY 70.66% OF THE
      OUTSTANDING CANNIMED SHARES) HAVE BEEN TAKEN-UP BY AURORA UNDER THE OFFER
      TO THE DATE HEREOF. </P></TD></TR></TABLE></DIV>
<P align=justify>This Notice of Variation and Extension should be read in
conjunction with the Original Offer and Circular and the Original Notice of
Variation. Except as otherwise set forth herein, the terms and conditions
previously set forth in the Original Offer and Circular continue to be
applicable in all respects. All references to the &#147;<B>Offer</B>&#146;&#146; in the
Original Offer and Circular, the Original Notice of Variation and this Notice of
Variation and Extension mean the Original Offer as amended by the Original
Notice of Variation and hereby, and all references in such documents to the
&#145;&#145;<B>Circular</B>&#146;&#146; or the &#145;&#145;<B>Offer and Circular</B>&#146;&#146; mean the Original Offer
and Circular as amended by the Original Notice of Variation and hereby. Unless
the context requires otherwise, capitalized terms used herein but not defined
herein that are defined in the Original Offer and Circular and the Original
Notice of Variation have the respective meanings given to them in the Original
Offer and Circular and the Original Notice of Variation. </P>
<P align=justify><B>How to Accept the Offer </B></P>
<P align=justify><B>CanniMed shareholders (the </B><B>&#147;</B><B>CanniMed
Shareholders</B><B>&#148;</B><B>) who have validly deposited and not withdrawn their
CanniMed Shares need take no further action to accept the Offer</B>. CanniMed
Shareholders whose CanniMed Shares are registered in their name and who wish to
accept the Offer must properly complete and execute the Amended Letter of
Transmittal that accompanied the Original Notice of Variation (printed on BLUE
paper) or a manually executed facsimile thereof, and deposit it, at or prior to
the Expiry Time, together with the DRS statement(s) representing their CanniMed
Shares, with the depository for the Offer, Laurel Hill Advisory Group
(&#147;<B>Laurel Hill</B>&#148; or the &#147;<B>Depository and Information Agent</B>&#148;) in
accordance with the instructions in the Amended Letter of Transmittal.
Alternatively, CanniMed Shareholders may follow the procedure for Book based
Transfer set forth in Section 3 of the Original Offer &#147;<B>Manner of Acceptance
</B><B>-</B><B> Procedure for Book-based Transfer</B>&#148;.</P>
<P align=justify>CanniMed Shareholders whose CanniMed Shares are held on their
behalf, or for their account, by an investment dealer, broker, bank, trust
company or other intermediary, should contact their intermediary directly if
they wish to accept the Offer. Intermediaries will likely establish tendering
cut-off times that are up to 48 hours prior to the Expiry Time. As a result,
CanniMed Shareholders who wish to tender their CanniMed Shares to the Offer and
whose CanniMed Shares are held through an intermediary should promptly and
carefully follow the instructions provided to them by their investment dealer,
broker, bank, trust company or other intermediary. </P>
<P align=justify><B>Shareholder Questions</B></P>
<P align=justify>Questions and requests for assistance may be directed to Laurel
Hill. Additional copies of the Offer Documents and the Amended Letter of
Transmittal may also be obtained without charge from Laurel Hill. Contact
details may be found on the back page of this document. Copies of this
document and related materials may also be found on Aurora&#146;s website at
www.auroramj.com or on CanniMed&#146;s SEDAR profile at www.sedar.com. This SEDAR
website address is provided for informational purposes only and no information
contained on, or accessible from, this website is incorporated by reference in
this document unless otherwise expressly noted herein.</P>
<P align=center>(ii) </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_3></A>
<P align=justify>No broker, dealer, salesperson or other person has been
  authorized to give any information or make any representation other than those
  contained in this Notice of Variation and Extension, the Original Offer and
  Circular or the Original Notice of Variation, and, if given or made, such
  information or representation must not be relied upon as having been authorized
by the Offeror. </P>
<P align=center><B>QUESTIONS MAY BE DIRECTED TO THE INFORMATION AGENT </B></P>
<P align=center><IMG src="exhibit1-1x3x1.jpg" border=0> </P>
<P align=center>Laurel Hill Advisory Group<BR>70 University Avenue, Suite
1440<BR>Toronto, ON M5J 2M4</P>
<P align=center><B>North American Toll Free Phone:
</B>1-877-452-7184<BR><B>Outside of North America:
</B>1-416-304-0211<BR><B>Facsimile</B>: 1-416-646-2415<BR><B>E-mail</B>:
assistance@laurelhill.com <B></B><BR></P>
<P align=center>(iii) </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_4></A>
<P align=center><B>Contents</B><B> </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=left bgColor=#eeeeee><A
      href="#page_5">1.
      </A></TD>
    <TD noWrap align=left width="85%" bgColor=#eeeeee><A
      href="#page_5">VARIATION
      AND EXTENSION OF THE OFFER </A></TD>
    <TD noWrap align=left width="10%" bgColor=#eeeeee><A
      href="#page_5">2
  </A></TD></TR>
  <TR>
    <TD noWrap align=left>&nbsp;</TD>
    <TD noWrap align=left width="85%">&nbsp;</TD>
    <TD noWrap align=left width="10%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_5">2.
      </A></TD>
    <TD align=left width="85%" bgColor=#eeeeee><A
      href="#page_5">MANNER
      OF ACCEPTANCE </A></TD>
    <TD align=left width="10%" bgColor=#eeeeee><A
      href="#page_5">2
      </A></TD></TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="85%">&nbsp;</TD>
    <TD align=left width="10%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_5">3.
      </A></TD>
    <TD align=left width="85%" bgColor=#eeeeee><A
      href="#page_5">TAKE-UP
      AND PAYMENT FOR DEPOSITED CANNIMED SHARES </A></TD>
    <TD align=left width="10%" bgColor=#eeeeee><A
      href="#page_5">2
      </A></TD></TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="85%">&nbsp;</TD>
    <TD align=left width="10%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_6">4.
      </A></TD>
    <TD align=left width="85%" bgColor=#eeeeee><A
      href="#page_6">RIGHT
      TO WITHDRAW DEPOSITED CANNIMED SHARES </A></TD>
    <TD align=left width="10%" bgColor=#eeeeee><A
      href="#page_6">3
      </A></TD></TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="85%">&nbsp;</TD>
    <TD align=left width="10%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_6">5.
      </A></TD>
    <TD align=left width="85%" bgColor=#eeeeee><A
      href="#page_6">CONSEQUENTIAL
      AMENDMENTS TO THE ORIGINAL OFFER AND CIRCULAR AND OTHER DOCUMENTS </A></TD>
    <TD align=left width="10%" bgColor=#eeeeee><A
      href="#page_6">3
      </A></TD></TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="85%">&nbsp;</TD>
    <TD align=left width="10%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_6">6.
      </A></TD>
    <TD align=left width="85%" bgColor=#eeeeee><A
      href="#page_6">NOTICE
      AND DELIVERY </A></TD>
    <TD align=left width="10%" bgColor=#eeeeee><A
      href="#page_6">3
      </A></TD></TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="85%">&nbsp;</TD>
    <TD align=left width="10%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_6">7.
      </A></TD>
    <TD align=left width="85%" bgColor=#eeeeee><A
      href="#page_6">STATUTORY
      RIGHTS </A></TD>
    <TD align=left width="10%" bgColor=#eeeeee><A
      href="#page_6">3
      </A></TD></TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="85%">&nbsp;</TD>
    <TD align=left width="10%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_6">8.
      </A></TD>
    <TD align=left width="85%" bgColor=#eeeeee><A
      href="#page_6">DIRECTORS&#146;
      APPROVAL </A></TD>
    <TD align=left width="10%" bgColor=#eeeeee><A
      href="#page_6">3
      </A></TD></TR></TABLE>
<P align=center>- 1 - </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_5></A>
<P align=center><B>NOTICE OF VARIATION AND EXTENSION </B></P>
<P align=justify><I>This Notice of Variation and Extension extends the time
during which CanniMed Shareholders may tender their CanniMed Shares under the
Offer. Except as otherwise set out in this Notice of Variation and Extension,
the information, terms and conditions set out in the Original Offer and
Circular, the Original Notice of Variation, and the Amended Letter of
Transmittal continue to be applicable in all respects. </I><I>All references to
the &#145;&#145;Offer&#146;&#146; in the </I><I>Original Offer and Circular, the Original Notice of
Variation and this Notice of Variation and Extension mean the Original Offer as
amended hereby and by the Original Notice of Variation and all references in
such documents to </I><I>the &#145;&#145;Offer&#146;&#146; and/or &#145;&#145;Circular&#146;&#146; mean the Original
Offer and the Circular as amended hereby and by the </I><I>Original Notice of
Variation. </I></P>
<P align=right><B>MARCH 9, 2018 </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%"><B>1.</B> </TD>
    <TD>
      <P align=justify><B>VARIATION AND EXTENSION OF THE
  OFFER</B></P></TD></TR></TABLE>
<P align=justify>With effect as of 11:59 p.m. (Pacific time) on March 9, 2018,
the Offeror extended the time for acceptance of the Offer until 11:59 p.m.
(Pacific time) on March 24, 2018, or until such later time and date as may be
fixed by the Offeror from time to time pursuant to Section 5 of the Offer to
Purchase, &#147;Acceleration, Extension and Variation of the Offer&#148;.</P>
<P align=justify>Accordingly, the &#147;<B>Expiry Time</B>&#148; of the Offer is now 11:59
p.m. (Pacific time) on March 24, 2018 subject to further extension of the Offer
by the Offeror from time to time pursuant to Section 5 of the Offer to Purchase,
&#147;Acceleration, Extension and Variation of the Offer&#148;. If the Offeror elects to
further extend the period during which CanniMed Shareholders may tender their
CanniMed Shares under the Offer, it will publicly announce details of the
extension, as required by applicable Canadian Securities Laws, and will mail a
copy of the notice of extension to registered CanniMed Shareholders who are
entitled to receive notice under applicable Canadian Securities Laws. </P>
<P align=justify>In addition, all references to March 9, 2018 in the Original
Offer and Circular, Original Notice of Variation, and Amended Letter of
Transmittal to the Expiry Time are amended to refer to March 24, 2018.</P>
<P align=justify>Other than as described in this Notice of Variation and
Extension, the other terms of the Offer remain unchanged. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%"><B>2.</B> </TD>
    <TD>
      <P align=justify><B>MANNER OF ACCEPTANCE</B></P></TD></TR></TABLE>
<P align=justify>CanniMed Shares not previously tendered to the Offer may be
deposited under the Offer in accordance with Section 7 of the Original Notice of
Variation, &#147;Manner of Acceptance&#148;. CanniMed Shareholders should tender their
CanniMed Shares to the Offer by using the Amended Letter of Transmittal.</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%"><B>3.</B> </TD>
    <TD>
      <P align=justify><B>TAKE-UP AND PAYMENT FOR DEPOSITED CANNIMED
      SHARES</B></P></TD></TR></TABLE>
<P align=justify>As of 11:59 p.m. (Pacific time) on March 8, 2018, a total of
17,847,341<B> </B>CanniMed Shares, representing 70.66% of the outstanding
CanniMed Shares, had been deposited to the Offer and not withdrawn. With all of
the conditions to the Offer having been met, Aurora will immediately take up the
deposited CanniMed Shares and pay for the CanniMed Shares taken up as soon as
possible and in any event not later than 3 business days after the CanniMed
Shares are taken up. Pursuant to elections made by the CanniMed Shareholders,
Aurora will issue approximately 50.6 million Aurora Shares and pay approximately
$98 million in cash. Aurora will take up and pay for the CanniMed Shares in the
manner set out in Section 8 of the Original Notice of Variation, &#147;Take-up and
Payment for Deposited CanniMed Shares&#148; and as required by applicable Canadian
Securities Laws. </P>
<P align=justify>For CanniMed Shares deposited after 11:59 p.m. (Pacific time)
on March 8, 2018, during the Mandatory Extension Period, Aurora will take up and
pay for such CanniMed Shares validly deposited under the Offer in the manner set
out in Section 8 of the Original Notice of Variation, &#147;Take-up
and Payment for Deposited CanniMed Shares&#148; and as required by applicable
Canadian Securities Laws. </P>
<P align=center>- 2 - </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_6></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%"><B>4.</B> </TD>
    <TD>
      <P align=justify><B>RIGHT TO WITHDRAW DEPOSITED CANNIMED
  SHARES</B></P></TD></TR></TABLE>
<P align=justify>CanniMed Shareholders have the right to withdraw CanniMed
Shares deposited under the Offer in the manner set forth in Section 6 of the
Original Offer, &#145;&#145;Withdrawal of Deposited CanniMed Shares&#146;&#146;. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%"><B>5.</B> </TD>
    <TD>
      <P align=justify><B>CONSEQUENTIAL AMENDMENTS TO THE ORIGINAL OFFER AND
      CIRCULAR AND OTHER DOCUMENTS</B></P></TD></TR></TABLE>
<P align=justify>The Original Offer and Circular, Original Notice of Variation
and Amended Letter of Transmittal shall be read together with this Notice of
Variation and Extension and are hereby amended to the extent necessary to
reflect the amendments contemplated by, and the information contained in, this
Notice of Variation and Extension. Except as otherwise set forth in or amended
by this Notice of Variation and Extension, the terms and conditions of the Offer
and the information in the Original Offer and Circular, Original Notice of
Variation and Amended Letter of Transmittal continue to be applicable in all
respects. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%"><B>6.</B> </TD>
    <TD>
      <P align=justify><B>NOTICE AND DELIVERY</B></P></TD></TR></TABLE>
<P align=justify>The Original Offer and Circular, the Notice of Change, the
Original Notice of Variation, the Letter of Transmittal that accompanied the
Original Offer and Circular, the Amended Letter of Transmittal that accompanied
the Original Notice of Variation were, and this Notice of Variation and
Extension is being sent to registered owners of CanniMed Shares. The Offeror
does not intend to send this Notice of Variation and Extension to non-registered
owners of CanniMed Shares generally, but may determine to send this Notice of
Variation and Extension to selected non-registered owners of CanniMed Shares in
response to requests or otherwise. If you are a non-registered owner of CanniMed
Shares, and the Offeror or its agent has sent these materials directly to you,
your name and address and information about your holdings of CanniMed Shares
have been obtained, in accordance with applicable regulatory requirements, from
the intermediary holding such securities on your behalf. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%"><B>7.</B> </TD>
    <TD>
      <P align=justify><B>STATUTORY RIGHTS</B></P></TD></TR></TABLE>
<P align=justify>Securities legislation of the provinces and territories of
Canada provides CanniMed Shareholders with, in addition to any other rights they
may have at law, one or more rights of rescission, price revision or to damages
if there is a misrepresentation in a circular or notice that is required to be
delivered to those security holders. However, such rights must be exercised
within prescribed time limits. CanniMed Shareholders should refer to the
applicable provisions of the securities legislation of their province or
territory for particulars of those rights or consult a lawyer. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%"><B>8.</B> </TD>
    <TD>
      <P align=justify><B>DIRECTORS&#146; APPROVAL</B></P></TD></TR></TABLE>
<P align=justify>The contents of this Notice of Variation and Extension have
been approved and the sending thereof to the CanniMed Shareholders has been
authorized by the Aurora Board. </P>
<P align=center>- 3 - </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_7></A>
<P align=center><B>FORWARD-LOOKING STATEMENTS </B></P>
<P align=justify>This Notice of Variation and Extension contains certain
forward-looking information (referred to herein as &#147;<B>forward-looking
statements</B>&#148;). Forward-looking statements are often, but not always,
identified by the use of words such as &#147;anticipate&#148;, &#147;believe&#148;, &#147;plan&#148;,
&#147;scheduled&#148;, &#147;intend&#148;, &#147;objective&#148;, &#147;continuous&#148;, &#147;ongoing&#148;, &#147;estimate&#148;,
&#147;expect&#148;, &#147;may&#148;, &#147;will&#148;, &#147;project&#148;, &#147;should&#148;, or similar words suggesting future
events, circumstances or outcomes.</P>
<P align=justify>In particular, this Notice of Variation and Extension contains
forward-looking information concerning the Original Offer and Original Notice of
Variation, and other statements that are not historical facts, in addition to
certain statements and information contained elsewhere in this document and in
the documents incorporated by reference concerning the business, operations and
financial performance and condition of the Offeror and CanniMed that are not
historical facts and are forward-looking statements or forward-looking
information within the meaning of applicable securities laws. All such
forward-looking statements are subject to important risks, uncertainties and
assumptions. It is important to know that:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="5%" >&#149; </TD>
    <TD align=left width="90%">
      <P align=justify>unless otherwise indicated, forward-looking statements in
      this document describe the Offeror&#146;s expectations as at March 9, 2018 and,
      accordingly, are subject to change after such date; </P></TD></TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD width="5%" >&nbsp; </TD>
    <TD width="90%">
      <P align=justify></P></TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="5%" >&#149; </TD>
    <TD align=left width="90%">
      <P align=justify>forward-looking statements in the documents incorporated
      by reference herein are as at the dates specified in the applicable
      documents and are expressly qualified by the statements made therein;
    </P></TD></TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD width="5%" >&nbsp; </TD>
    <TD width="90%">
      <P align=justify></P></TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="5%" >&#149; </TD>
    <TD align=left width="90%">
      <P align=justify>the Offeror&#146;s actual results and events could differ
      materially from those expressed or implied in the forward-looking
      statements in this document or documents incorporated by reference herein,
      if known or unknown risks affect the business of the Offeror, or if its
      estimates or assumptions turn out to be inaccurate. As a result, the
      Offeror cannot guarantee that the results or events expressed or implied
      in any forward-looking statement will materialize, and accordingly, you
      are cautioned against relying on these forward-looking statements; and
    </P></TD></TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD width="5%" >&nbsp; </TD>
    <TD width="90%">
      <P align=justify></P></TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="5%" >&#149; </TD>
    <TD align=left width="90%">
      <P align=justify>the Offeror disclaims any intention and assumes no
      obligation to update or revise any forward -looking statement even if new
      information becomes available, as a result of future events or for any
      other reason, except in accordance with applicable Canadian Securities
      Laws. </P></TD></TR></TABLE>
<P align=justify>Forward-looking statements are based upon, among other things,
the opinions and expectations of management of the Offeror as at the effective
date of such statements and, in some cases, information supplied by third
parties. Although the Offeror believes the opinions and expectations reflected
in such forward-looking statements are based upon reasonable assumptions and
that information received from third parties is reliable, it can give no
assurance that those opinions and expectations will prove to have been correct.
The Offeror made a number of assumptions in making forward-looking statements in
the Original Offer, the Circular and the Original Notice of Variation, including
the documents incorporated by reference. </P>
<P align=justify>Forward-looking information respecting the Offer, various terms
of the Offer and the anticipated timing of certain steps or events associated
with the Offer is based upon various assumptions and factors, including publicly
reported financial information concerning CanniMed, publicly reported
information concerning the number of outstanding CanniMed Shares and the number
of options and other convertible or exchangeable rights and securities granted
by CanniMed (entitling holders thereof to acquire CanniMed Shares), advice from
professional advisors with respect to statutorily mandated time frames for
various applications and steps/events associated with the Offer, that CanniMed
has made full and accurate disclosure of all material information concerning
CanniMed in accordance with applicable Canadian Securities Laws (including
disclosure of all material contracts and existing and potential contingent
liabilities) and that there have been no material changes in the business,
affairs, capital, prospects or assets of CanniMed. Forward-looking information
concerning possible synergies and efficiencies that may be achieved upon a
combination of the businesses of the Offeror and CanniMed and other benefits of
a combination of the businesses of the Offeror and CanniMed is based upon
various assumptions and factors, including (in addition to assumptions and factors
noted above and elsewhere in this document), financial information of CanniMed
available through publicly filed documents and the Offeror&#146;s general industry
knowledge and experience. Forward-looking information concerning the business
and geographical diversification that may be achieved upon a combination of the
businesses of the Offeror and CanniMed is based upon various assumptions and
factors, including (in addition to assumptions and factors noted above and
elsewhere in this document) publicly available information concerning the
location and size of various CanniMed operating facilities and the Offeror&#146;s
general industry knowledge and experience. Forward-looking information
concerning the anticipated market capitalization of the Offeror following
successful completion of the Offer is based upon various assumptions and factors
including the current market capitalization of both the Offeror and CanniMed,
advice from the Offeror&#146;s financial advisor, the absence of market disruptions
that would affect the trading price ofAurora Shares and the absence of material
adverse changes or developments affecting the Offeror or CanniMed.</P>
<P align=center>- 4 - </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_8></A>
<P align=justify>Additional risk factors could cause actual results or events to
  differ materially from the results or outcomes expressed or implied by the
  forward-looking statements in this document and various documents incorporated
  by reference herein. For a discussion regarding such risks, see, in particular,
  the sections of the Circular entitled &#147;Purpose of the Offer and Plans for
  CanniMed&#148;, &#147;Certain Information Concerning Securities of the Offeror&#148;,
  &#147;Regulatory Matters&#148; and &#147;Risk Factors&#148;, as well as the information contained
  under the heading &#147;Risk Factors&#148; in each of the documents incorporated by
  reference. The Offeror cautions you that the risks described or referenced in
  this section are not the only ones that could affect the Offer or the Offeror.
  Additional risks and uncertainties not presently known by the Offeror or that
  the Offeror currently believes are not material may also materially and
  adversely affect the receipt of the Regulatory Approvals, the satisfaction or
  waiver by the Offeror of any of the conditions of the Offer, the successful
  completion of the Offer or the business, operations, financial condition,
  financial performance, cash flows, reputation or prospects of the Offeror.
  Except as otherwise indicated by the Offeror, forward-looking statements do not
  reflect the potential impact of any special initiatives or of any dispositions,
  monetizations, mergers, acquisitions, other business combinations or other
  transactions that may be announced or that may occur after March 9, 2018. The
  financial impact of any such special initiatives or transactions may be complex
  and will depend on the facts particular to each of them. The Offeror, therefore,
  cannot describe the expected effects in a meaningful way or in the same way it
  presents known risks affecting its business. Forward-looking statements are
  presented herein for the purpose of providing information about the Offeror and
the Offer and its anticipated impacts. </P>
<P align=center><B>INFORMATION CONCERNING CANNIMED</B></P>
<P align=justify>Except as otherwise expressly indicated herein, the information
concerning CanniMed contained in the Original Offer and Circular and the
Original Notice of Variation has been taken from and is based solely upon
CanniMed&#146;s public disclosure, including disclosure on file with the Canadian
securities regulatory authorities. CanniMed has not reviewed the Original Offer
and Circular and the Original Notice of Variation and has not confirmed the
accuracy and completeness of the information in respect of CanniMed contained in
the Original Offer and Circular and the Original Notice of Variation. Although
Aurora has no knowledge that would indicate that any information or statements
contained in the Original Offer and Circular and the Original Notice of
Variation concerning CanniMed taken from, or based upon, such public disclosure
contain any untrue statement of a material fact or omit to state a material fact
that is required to be stated or that is necessary to make a statement not
misleading in light of the circumstances in which it was made, neither Aurora
nor any directors or officers of Aurora have verified, nor do they assume any
responsibility for, the accuracy or completeness of such information or
statements or for any failure by CanniMed to disclose events or facts which may
have occurred or which may affect the significance or accuracy of any such
information or statements but which are unknown to Aurora.</P>
<P align=center><B>GENERAL INFORMATION </B></P>
<P align=justify>Calculations of percentage amounts or amounts per CanniMed
Share set forth in this Notice of Variation and Extension are based on
24,834,298 CanniMed Shares outstanding on a non-diluted basis and 25,259,022
CanniMed Share outstanding on a fully-diluted basis as of the close of business
on March 8, 2018.</P>
<P align=center>- 5 - </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_9></A>
<P align=justify>Unless otherwise noted herein, all references to &#147;$&#148; in this
Notice of Variation and Extension mean Canadian dollars. </P>
<P align=center><B>NOTICE TO CANNIMED SHAREHOLDERS IN THE UNITED STATES </B></P>
<P align=justify>The Offer is being made for the securities of a Canadian
foreign private issuer that does not have securities registered under Section 12
of the U<I>.S. </I>Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange
Act</B>&#148;). Accordingly, the Offer is not subject to Section 14(d) of the
Exchange Act, or Regulation 14D promulgated thereunder.</P>
<P align=justify>The Aurora Shares offered as consideration under the Offer are
being offered pursuant to an exemption from the registration requirements of the
United States Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder (the &#147;<B>US Securities Act</B>&#148;), provided by Rule 802
thereunder. No Aurora Shares will be delivered in the United States or for the
account or for the benefit of a person in the United States, unless the Offeror
is satisfied that such Aurora Shares may be delivered in the relevant
jurisdiction in reliance upon available exemptions from the registration
requirements of the US Securities Act and the securities Laws of the relevant
United States state or other local jurisdiction, or on a basis otherwise
determined to be acceptable to the Offeror in its sole discretion, and without
subjecting the Offeror to any registration or similar requirements.</P>
<P align=justify>US CanniMed Shareholders that hold &#147;restricted securities&#148; as
defined in Rule 144 under the US Securities Act will receive Aurora Shares that
are restricted to the same extent, including legends, and proportion that the
Aurora Shares held by US Aurora Shareholders are restricted securities.
Restricted securities may be offered, sold, pledged or otherwise transferred,
directly or indirectly, only pursuant to a subsequent registration statement or
an exemption or exclusion from the registration requirements of the US
Securities Act and applicable state securities Laws.</P>
<P align=justify>On November 27, 2017, the Offeror furnished to the United
States Securities and Exchange Commission (the &#147;SEC&#148;) a Form CB &#150; Tender
Offer/Rights Offering Notification Form (a &#147;<B>Form CB</B>&#148;) in respect of the
offer and the sale of the Aurora Shares as described in the Original Offer and
the Offeror&#146;s takeover bid circular that accompanied the Original Offer (the
&#147;<B>Original Circular</B>&#148;). On January 16, 2018, the Offeror furnished to the
SEC as an exhibit to Amendment No. 1 a Notice of Change dated January 12, 2018,
which revised and updated certain information contained in the Original Offer
and the Original Circular. This Notice of Variation and Extension (i) amends the
terms set out in the Original Offer, (ii) updates certain information set out in
the Original Offer and the Original Circular, as amended by the Notice of
Change; and (iii) amends the letter of transmittal and exercise form to
accommodate the election of the CanniMed Shareholders to receive Aurora Shares,
cash, or a combination thereof, subject to pro ration. On February 7, 2018 the
Offeror furnished the Original Notice of Variation to the SEC as an exhibit to
Amendment No. 5 to the Form CB.</P>
<P align=justify>The Offeror will furnish this Notice of Variation and Extension
to the SEC as an exhibit to Amendment No. 7 to the Form CB. The Offeror has
mailed this Notice of Variation and Extension to CanniMed Shareholders. CanniMed
Shareholders are urged to read this Notice of Variation and Extension and any
other relevant documents to be filed with the SEC because they will contain
important information. Investors and security holders will be able to obtain the
documents free of charge at the SEC&#146;s website, www.sec.gov. In addition,
documents filed with the SEC by the Offeror will be available free of charge
from the Offeror. You should direct requests for documents to Laurel Hill
Advisory Group, 70 University Avenue, Suite 1440, Toronto, Ontario, M5J 2M4,
North American Toll Free Phone: 1-877-452-7184, outside North America Phone:
1-416-304-0211. To obtain timely delivery, such documents should be requested
not later than five (5) business days prior to the Expiry Time (as defined
herein).</P>
<P align=justify>The Offer is being conducted in accordance with Rule 802,
Section 14(e) of the Exchange Act and Regulation 14E promulgated thereunder. The
Offeror, a Canadian foreign private issuer, is permitted to prepare the Offer
and Notice of Variation and Extension in accordance with the disclosure
requirements of applicable Canadian provincial securities laws, and in
accordance with applicable Canadian federal and provincial corporate and
takeover offer rules.</P>
<P align=center>- 6 - </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_10></A>
<P align=justify>The Offer is being made for the securities of a Canadian issuer
and by a Canadian issuer that is permitted to prepare the Original Offer and
Circular and this Notice of Variation and Extension in accordance with the
disclosure requirements in force in Canada. CanniMed Shareholders in the United
States should be aware that such requirements are different from those of the
United States. The financial statements included or incorporated by reference
herein have been prepared in accordance with IFRS, and may be subject to
Canadian auditing and auditor independence standards, and thus may not be
comparable to financial statements of U.S. companies.</P>
<P align=justify>CanniMed Shareholders in the United States should be aware that
the disposition of their CanniMed Shares and the acquisition of Aurora Shares by
them as described herein may have tax consequences both in the United States and
in Canada. Such consequences for investors who are resident in, or citizens of,
the United States may not be described fully herein and such CanniMed
Shareholders are encouraged to consult their tax advisors. See also &#147;Certain
Canadian Federal Income Tax Considerations&#148; and &#147;Certain United States Federal
Income Tax Considerations&#148; in the Original Notice of Variation.</P>
<P align=justify>The enforcement by CanniMed Shareholders of civil liabilities
under U.S. federal securities laws may be affected adversely by the fact that
the Offeror is incorporated under the laws of British Columbia, Canada, and
CanniMed is incorporated under the federal laws of Canada, that some or all of
their respective officers and directors may be residents of a foreign country,
that some or all of the experts named herein may be residents of a foreign
country and that all or a substantial portion of the assets of the Offeror and
CanniMed and said Persons may be located outside the United States. CanniMed
Shareholders may not be able to sue the Offeror or CanniMed or their officers or
directors in a foreign court for violations of the U.S. securities laws. It may
be difficult to compel the Offeror or CanniMed or their respective affiliates
(as defined herein) to subject themselves to a U.S. court&#146;s judgment.</P>
<P align=justify>You should be aware that the Offeror may purchase securities
otherwise than under the Offer, subject to compliance with applicable Canadian
Securities Laws.</P>
<P align=justify>THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE
SEC OR ANY U.S. STATE SECURITIES COMMISSION NOR HAS THE SEC OR ANY U.S. STATE
SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THE OFFER AND
CIRCULAR. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</P>
<P align=justify>In accordance with Rule 802, the Offer is not required to be
extended to security holders in those states that require registration or
qualification.</P>
<P align=justify>THESE SECURITIES HAVE NOT BEEN REGISTERED OR OTHERWISE
QUALIFIED FOR OFFER AND SALE IN CERTAIN U.S. STATES WHERE HOLDERS OF CANNIMED
SHARES RESIDE AND NO SUCH OFFER TO SELL OR SALE, OR SOLICITATION OF AN OFFER TO
BUY MAY BE MADE IN SUCH U.S. STATES.</P>
<P align=center>- 7 - </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_11></A>
<P align=center><B>CERTIFICATE OF AURORA CANNABIS INC. </B></P>
<P align=justify>Dated: March 9, 2018 </P>
<P align=justify>The foregoing, together with the Original Offer and Circular,
as amended by the Notice of Change, and the Original Notice of Variation,
contains no untrue statement of a material fact and does not omit to state a
material fact that is required to be stated or that is necessary to make a
statement not misleading in the light of the circumstances in which it is made.
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><I>(signed) </I>Terry Booth </TD>
    <TD align=center width="50%"><I>(signed) </I>Glen Ibbott </TD></TR>
  <TR vAlign=top>
    <TD align=center>Chief Executive Officer </TD>
    <TD align=center width="50%">Chief Financial Officer </TD></TR></TABLE>
<P align=center><B>On behalf of the Board of Directors </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><I>(signed) </I>Steve Dobler </TD>
    <TD align=center width="50%"><I>(signed) </I>Michael Singer </TD></TR>
  <TR vAlign=top>
    <TD align=center>Director </TD>
    <TD align=center width="50%">Director </TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_12></A>
<P align=center>The Depositary and Information Agent for the Offer is:</P>
<P align=center><IMG src="exhibit1-1x12x1.jpg" border=0> </P>
<P align=center>Laurel Hill Advisory Group<BR>70 University Avenue, Suite
1440<BR>Toronto, ON M5J 2M4</P>
<P align=center><B>North American Toll Free Phone: </B><BR>1-877-452-7184</P>
<P align=center><B>Outside of North America: </B><BR>1-416-304-0211<BR></P>
<P align=center><B>Facsimile</B>: 1-416-646-2415</P>
<P align=center><B>E-mail</B>: assistance@laurelhill.com</P>
<P align=center><B>Questions and requests for assistance may be directed to the
Depositary and Information </B><BR><B>Agent at the telephone numbers and
location set out above. </B></P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.2
<SEQUENCE>3
<FILENAME>exhibit1-2.htm
<DESCRIPTION>EXHIBIT 1.2
<TEXT>
<HTML>
<HEAD>
   <TITLE>Aurora Cannabis Inc.: Exhibit 1.2 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<!--$$/page=--><A name=page_1></A>
<P align=justify><B><font size="3">Aurora Cannabis Succeeds in Bid for CanniMed - Takes Up
Shares</font></B></P>
<P align=center><B>Announces Mandatory Extension of Tender Period</B></P>
<P align=justify>TSX: ACB</P>
<P align=justify>EDMONTON, March 9, 2018 /CNW/ - Aurora Cannabis Inc.
("<B>Aurora</B>") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM)
announced today that the Company has been successful in its offer (the
"<B>Offer</B>") for all the issued and outstanding common shares for CanniMed
Therapeutics Inc. ("<B>CanniMed</B>").</P>
<P align=justify>The number of CanniMed common shares (the "<B>CanniMed
Shares</B>") tendered as at the close of business on March 8, 2018 totals
17,847,341, representing approximately 70.66% of the total outstanding CanniMed
Shares on a fully diluted basis. All of the conditions to the Offer having been
met, Aurora will take up the tendered CanniMed Shares and pay for those shares
as soon as possible, and in any event not later than 3 business days after the
CanniMed Shares are taken up. Aurora will issue a total of approximately 50.6
million Aurora common shares and pay a total of approximately $98
million in cash for the CanniMed Shares tendered as of March 8, 2018.</P>
<P align=justify>"Following the take up, we will immediately commence with the
integration of CanniMed into the Aurora organization and start executing on
realizing the strategic synergies we have identified," said Terry Booth, CEO.
"Combining two of the leading international cannabis brands creates a company
that is exceptionally well positioned to capitalize on the tremendous
opportunities in the domestic and international medical markets, as well as the
Canadian adult consumer use market, once legalized. We look forward to working
closely with our new colleagues to establish Aurora's Medical Cannabis Centre of
Excellence."</P>
<P align=justify><B>Mandatory Extension</B></P>
<P align=justify>In addition, pursuant to applicable Canadian securities laws
requiring Aurora to extend its Offer, the Company has extended the period
shareholders of CanniMed have to tender their shares under the Offer by 15 days
to 11.59 pm (Pacific Time) March 25, 2018. Aurora has provided notice of the
extension to Laurel Hill Advisory Group (the "<B>Depositary and Information
Agent</B>") effective March 9, 2018. There is no guarantee that Aurora will
further extend the Offer after March 24, 2018, and CanniMed shareholders are
encouraged to tender as soon as possible.</P>
<P align=justify>Full details of the extension of the period during which
additional CanniMed Shares may be tendered under the Offer will be included in a
notice of variation and extension (the "<B>Notice of Variation and
Extension</B>"), which Aurora expects to file on SEDAR (under CanniMed's
profile) at www.sedar.com and mail to registered CanniMed Shareholders on or
prior to March 9, 2018.</P>
<P align=justify><B>How to Tender</B></P>
<P align=justify>Aurora encourages CanniMed shareholders to read the full
details of the Offer set forth in its original offer and takeover bid circular
dated November 24, 2017 (as amended by its notice of change dated January 12,
2018), and its notice of variation dated February 5, 2018 and March 9, 2018, and
accompanying offer documents (collectively, the "<B>Offer Documents</B>"), which
contain detailed instructions on how CanniMed shareholders can tender their
CanniMed Common Shares to the Offer. For assistance in depositing CanniMed
Common Shares to the Offer, CanniMed shareholders should contact the Depository
and Information Agent for the Offer, Laurel Hill Advisory Group at Phone:
1-877-452-7184 (North American Toll Free Phone) and 1-416-304-0211 (Outside
North America); Facsimile: 416-646-2415; and E-mail:
assistance@laurelhill.com.</P>
<P align=justify><B>About the Offer</B></P>
<P align=justify>The full details of the Offer are set out in the Offer
Documents, which have been filed with the Canadian securities regulatory
authorities and have been mailed to CanniMed shareholders. The Offer Documents
are also available on SEDAR under CanniMed's profile at www.sedar.com. </P>
<P align=justify>Materials filed with the Canadian securities regulatory
authorities are available electronically without charge at www.sedar.com.
Materials filed with the SEC are available electronically without charge on
EDGAR accessable through the SEC's website at www.sec.gov. Documents related to
the Offer, including the Offer Documents, are also available on Aurora's website
at www.auroramj.com and shareholders are invited to visit cannimed.auroramj.com
for further information.</P>
<P align=justify><B>About Aurora</B></P>
<P align=justify>Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises
Inc., is a licensed producer of medical cannabis pursuant to Health Canada's
Access to Cannabis for Medical Purposes Regulations ("ACMPR"). The Company
operates a 55,200 square foot, state-of-the-art production facility in Mountain
View County, Alberta, known as "Aurora Mountain", and a second 40,000 square
foot high-technology production facility known as "Aurora Vie" in Pointe-Claire,
Quebec on Montreal's West Island. In January 2018, Aurora's 800,000 square foot
flagship cultivation facility, Aurora Sky, located at the Edmonton International
Airport, was licensed. Once at full capacity, Aurora Sky is expected to produce
over 100,000 kg per annum of cannabis. Aurora is completing a fourth facility in
Lachute, Quebec utilizing its wholly owned subsidiary Aurora Larssen Projects
Ltd.</P>
<P align=justify>Aurora also owns Berlin-based Pedanios, the leading wholesale
importer, exporter, and distributor of medical cannabis in the European
Union.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=justify>The Company owns 51% of Aurora Nordic, which will be
constructing a 1,000,000 square foot hybrid greenhouse in Odense, Denmark. The
Company offers further differentiation through its acquisition of BC Northern
Lights Ltd. and Urban Cultivator Inc., industry leaders, respectively, in the
production and sale of proprietary systems for the safe, efficient and
high-yield indoor cultivation of cannabis, and in state-of-the-art indoor
gardening appliances for the cultivation of organic microgreens, vegetables and
herbs in home and professional kitchens.</P>
<P align=justify>Aurora holds a 19.88% ownership interest in Liquor Stores N.A.,
who intend developing a cannabis retail network in Western Canada. In addition,
the Company holds approximately 17.23% of the issued shares in leading
extraction technology company Radient Technologies Inc., and has a strategic
investment in Hempco Food and Fiber Inc., with options to increase ownership
stake to over 50%. Aurora is also the cornerstone investor in two other licensed
producers, with a 22.9% stake in Cann Group Limited, the first Australian
company licensed to conduct research on and cultivate medical cannabis, and a
17.62% stake in Canadian producer The Green Organic Dutchman Ltd., with options
to increase to majority ownership.</P>
<P align=justify>Aurora's common shares trade on the TSX under the symbol "ACB".
</P>
<P align=justify>On behalf of the Boards of Directors,</P>
<P align=justify>AURORA CANNABIS INC. <BR>Terry Booth<BR>CEO</P>
<P align=justify><B>Shareholder Questions</B></P>
<P align=justify>Questions may be directed to Aurora's Information Agent at:</P>
<P align=justify><B>Laurel Hill Advisory Group</B><BR>North America Toll Free:
1-877-452-7184<BR>Collect Calls Outside North America: 1-416-304-0211<BR>Email:
assistance@laurelhill.com</P>
<P align=justify><B>Forward-Looking Information Cautionary Statement</B></P>
<P align=justify><I>This news release contains certain "forward-looking
statements" within the meaning of such statements under applicable securities
law. Forward-looking statements are frequently characterized by words such as
"plan", "continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other similar words, or
statements that certain events or conditions "may" or "will" occur. These
statements are only predictions. Forward looking statements in release include
statements regarding the proposed integration of CanniMed with Aurora, the
expected benefits of that integration, the timing of the take up and payment for
the CanniMed Shares, and whether there will be any further extension of the
Offer. Various assumptions were used in drawing the conclusions or making the
projections contained in the forward-looking statements throughout this news
release, including assumptions based upon CanniMed's publicly disclosed
information, and that there will be no change in the business, prospects or
capitalization of CanniMed or Aurora. Forward-looking statements are based on
the opinions and estimates of management at the date the statements are made,
and are subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those projected
in the forward-looking statements. The Company is under no obligation, and
expressly disclaims any intention or obligation, to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise, except as expressly required by applicable law. A more
complete discussion of the risks and uncertainties facing the Company appears in
the Company's Annual Information Form and continuous disclosure filings, which
are available at </I><I>www.</I><I>sedar.</I><I>com</I><I>. </I></P>
<P align=justify><I>Neither TSX nor its Regulation Services Provider (as that
term is defined in the policies of Toronto Stock Exchange) accepts
responsibility for the adequacy or accuracy of this release.</I></P>
<P align=justify><B>Notice to U.S. Holders</B></P>
<P align=justify><I>The Offer is made for the securities of a company formed
outside of the United States. The Offer will be subject to disclosure
requirements of Canada that are different from those of the United States.
Financial statements included in the documents, if any, will be prepared in
accordance with Canadian accounting standards and may not be comparable to the
financial statements of United States companies.</I></P>
<P align=justify><I>It may be difficult for a securityholder in the United
States to enforce his/her/its rights and any claim a securityholder may have
arising under the U.S. federal securities laws, since the issuer is located in
Canada, and some or all of its officers or directors may be residents of Canada
or another country outside of the United States. A securityholder may not be
able to sue a Canadian company or its officers or directors in a court in Canada
or elsewhere outside of the United States for violations of U.S. securities
laws. It may be difficult to compel a Canadian company and its affiliates to
subject themselves to a U.S. court's judgment.</I></P>
<P align=justify><I>Securityholders should be aware that the issuer may purchase
securities otherwise than under the Offer, such as in open market or privately
negotiated purchases.</I></P>
<P align=justify><B>For further information: </B>For Aurora: Cam Battley, Chief
Corporate Officer, +1.905.864.5525, cam@auroramj.com, www.auroramj.com; Marc
Lakmaaker, Director, Investor Relations and Corporate Development,
+1.647.269.5523, marc.lakmaaker@auroramj.com </P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>exhibit1-1x1x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit1-1x1x1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1" !? *T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#T"BBB@ HH
MHH **** "BBDH 6BJUS<>4R(J[W;)VYQP.M065UOD>%Y5=Q\P(]#V_#I^5.S
MM<AS2=C0HKF3_P AW_MM_6M+5[YK;RTB/SD[C]/2M)4FFDNIC'$)QE*2M8U*
M*AMYEN(4E7HPZ5+WK(Z$[JZ%HHHH&%%%% !1110 4444 %%%% !1110 4444
M %-/2G4T\B@#,U*Q^VS*?M"(%7&T]:BLM.-I<B47,9QP0!U'YU7N-(NGN)'&
MS:S$@ENV:C&C71P?W9_X%74DN6W,>9+FY^;V;OZC=P_MO=GCSLY_&M2_L([N
M991*@(&"">"*POL\@N/L^!OW;?;-7/[%N_2/_OJKFE=/FL94I2<7'DOJ;ELJ
M0Q+$'0X]#_2K%8-GI-S#=12/LVJV3AJWN]<LTD]'<]&C*4H^]&UA:***@W"B
MBB@ HHHH **** "BBB@ HHHH **** "DI:2@#+U2Y>$"15.Y",97CZ_3M^51
MZ7=/,=S#G(7Y1GCM^ _J*T9H!(P;@?WN/O#TID%N(V!R" !A0/NG&#BM.:/+
M:QSN$_:<U]##Z:Y_VW_K6NUTS+YC,R1M]P+@L?<Y_"JO]ES_ -I?: R>7YF[
MKSC.?2M V<))(#KDY(5RH_(&KJ2BVC*C"<5)>9'9W32ML?+-ZA,#^=7:CBB6
M(84M_P "8G^=2UB[-Z'7!-+4****104444 %%%% !1110 4E%<WJ?C&TT^_E
MM#;RRM$<%E(QF@#I**R="UZ#6TE:&-XS$0&5R,\]_P!*O:C=K86,UTZEEB7<
M0.IH L45S^C^*[?5K];6*VEC<J3N8C'%7]:U:/1K,7,L;R*7"87KDY]?I0!H
MT5BZ%XB@UN:6.&"2(Q*&.\CGGVJ+6?%-OH]]]EEMY9&V!\J1CF@#?HKD?^$^
MLO\ GSG_ #6K^E>+M/U*[6V"2PRO]WS ,$^F0: .@I*"P ))P!UKE[WQQI\$
MS1V\4MQM."XPJ_AGG]* .HHKD(_'UH6'F64RKW*L#^G%=/8WUOJ-JMQ:2B2-
MNX['TH L45SVK>+;;2M0>TEMI7= "64C'(S5+_A/K+_GSG_-: .NHK#T?Q58
M:M<?9T$D,V,JLF/F^A!K<H **QM=\0P:(\*30R2F4$@*1QBJ^D^+;75=02TC
MMY8W<$@L1C@9H Z&EJE+J"17JVS(Q+$#=QP3TJ[0!%<2B"WDE;I&A8_@,UY/
MIUE/K>I-'N)D</([8[XS_/'YUW?C;4/L>B/$I_>7)\L?3^+]./QKCO#.LPZ+
M=33RPO*738NT@8YR: )O!=V]IX@CBR0DX,;@^N,C]1C\:[CQ-_R+M]_UR->:
MR7P&MG4+="@\_P Y$/;YLXKT77)TNO"ES<1\I+!O7Z'!I <;X'_Y&./_ *YO
M_*NE\?\ _(!3_KX7^35S'@A@OB.'<0,HX'OQ72_$"1!HD2%@':=2!GGH:8&7
M\.O^/Z\_ZYK_ #JGX\_Y& ?]<5_F:N?#L_Z;>?\ 7-?YU3\>_P#(?'_7%?YF
MD!J>%_#NF:CHL=S=0%Y69@6\QAT..@-<A>H+/4[B.%F @F94.>1M;@_I5JSU
M'6+2RVVDMPELN2"J_*/7G%-T>Q.L:O';R3!#*2SLW)/<_B:8'H?B&>2/PQ=2
MHVUS$!D>Y /\ZX7PMI4.L:J8+EF$<<9D(4\G! QG\:[GQ6,>&;P 8PB\?\"%
M<EX!E2/79 S %X&503U.Y3C]#0!:\7>'+'3+".[L@\9\P(R%BP.<^O/:K'PY
M=C'?H2=H,; >YW9_D*N>/Y$&B)&S .TRD#N< U2^''_,1_[9?^S4 8WC7_D9
M;C_=3_T$5O>'_#.EW^AV]S<0,9I%.YQ(P_B(Z9K!\;?\C+<?[J?^@BJUOJ>L
MVM@JP37$=JH(!5?E SZX]32&4K=FM[^)XV(>.0%2/4&O9*\J\,Z8-5U>.-Y5
M14Q(0>K 'H*],U&Z%EIUQ<D9\J,L!ZG' IB///&MZ+O7GC0Y2W41C'KU/ZG'
MX50(GT+7!G(DMY ?3(_^N#5>UN$74(KFY5I5602.!U;G)_.KWB/58-8OTNH(
M7B.P*P8@Y(S@_P"?2@#TZ..WN!'<JB/N 97Q^1_6K%<_X)N3<>'8E)R86:,G
M]1^A%=!0!QOC?3M1U&]MA:6TDL4<9Y7&-Q/^ %3Z)X1L?[+A.I69:Z;)?+L,
M<\#@XZ5U=% '!>)?"C1W$+:/9N8V4AU5LX.>O)[Y_2MSPS:77_"/O8:I;NH!
M:,*_="/_ *YKH:* /,-2\*:I8SL88'N(@WR/%\QQVXZ@U5CT/6KN0*;&Z)Z9
ME4J!^+5ZS10!A>&- _L6V<R,'N9L;R.@ [#]:P?&.CZA?:T)K2TDEC\I1N7I
MG)KNZ* ,/PO8R6_AZ.UO82K$ON1QV)-<A>^&M6L=4D:PMY61'W121GH.H_P_
M"O2Z* ,NR2?4M#$6IP&.62,QRJ>_;(_G7!ZCX4U6PE_=0M<Q@_*\(R?RZYKU
M"B@#R>+0=9O)0#97.3QNF4J /J:[_P -:'_8ED\;N))I3N=AT]@*V:* //\
MQ7HFI7NO33VUG))&P7##&.%%=-H>GL/#,%C?0D$HRR1MVR36U10!YB_AW6].
MU$M9P2L8FS',F.?\BNJU[^TKWPO'%':.;J?:LR#&4QR?U'ZUTE% '#>&/"BR
M"Y;6K%A@J(@S$>N3P?I5S7_"=FNENVE61^U!A@"1B2,\]3BNMHH X[P39:GI
8US<0W=K)%!(H<%L8# X_D?TKL:** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>exhibit1-1x3x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit1-1x3x1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1" !" -X# 2(  A$! Q$!_\0
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MO^$ATS_GN_\ WXD_^)KF_A__ ,?%[CGY4_F:[;FK0TY-;F;_ ,)#IG_/=_\
MOQ)_\31_PD.F?\]W_P"_$G_Q-:7-'XTRM>YF_P#"0Z9_SW?_ +\2?_$T?\)#
MIG_/=_\ OQ)_\36E^-'XT!KW,W_A(=,_Y[O_ -^)/_B:/^$ATS_GN_\ WXD_
M^)K2_&B@/>[F;_PD.F?\]W_[\2?_ !-'_"0Z9_SW?_OQ)_\ $UI4<T![W?\
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K "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>exhibit1-1x12x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit1-1x12x1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1" !& -P# 2(  A$! Q$!_\0
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M_P"M)W$9_P!G@<>]3Z'J1U?3EO# (0[$!=^[@''/ K)\._\ 'SXB_P"OI_\
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# /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
